Perennial Allergic Rhinitis - Pipeline Review, H2 2016

  • ID: 3846529
  • Report
  • 51 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Faes Farma, S.A.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • MORE
Perennial Allergic Rhinitis - Pipeline Review, H2 2016

Summary

‘Perennial Allergic Rhinitis - Pipeline Review, H2 2016’, provides an overview of the Perennial Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Perennial Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Perennial Allergic Rhinitis and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis
- The report reviews pipeline therapeutics for Perennial Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Perennial Allergic Rhinitis therapeutics and enlists all their major and minor projects
- The report assesses Perennial Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Perennial Allergic Rhinitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Perennial Allergic Rhinitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Perennial Allergic Rhinitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Faes Farma, S.A.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Perennial Allergic Rhinitis Overview

Therapeutics Development

Pipeline Products for Perennial Allergic Rhinitis - Overview

Pipeline Products for Perennial Allergic Rhinitis - Comparative Analysis

Perennial Allergic Rhinitis - Therapeutics under Development by Companies

Perennial Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes

Perennial Allergic Rhinitis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Perennial Allergic Rhinitis - Products under Development by Companies

Perennial Allergic Rhinitis - Products under Investigation by Universities/Institutes

Perennial Allergic Rhinitis - Companies Involved in Therapeutics Development

Faes Farma, S.A.

Glenmark Pharmaceuticals Ltd.

Hisamitsu Pharmaceutical Co., Inc.

Merck & Co., Inc.

Pfizer Inc.

Shionogi & Co., Ltd.

VentiRx Pharmaceuticals, Inc.

Perennial Allergic Rhinitis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(levocabastine hydrochloride + mometasone furoate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

asapiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bilastine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

desloratadine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emedastine difumarate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSP-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06444752 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06444753 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTX-1463 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Perennial Allergic Rhinitis - Dormant Projects

Perennial Allergic Rhinitis - Discontinued Products

Perennial Allergic Rhinitis - Product Development Milestones

Featured News & Press Releases

Aug 13, 2015: PENDOPHARM announces Nasacort Allergy 24H Nasal Spray is now available without a prescription in Canadian Province

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Perennial Allergic Rhinitis, H2 2016

Number of Products under Development for Perennial Allergic Rhinitis - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Perennial Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016

Perennial Allergic Rhinitis - Pipeline by Faes Farma, S.A., H2 2016

Perennial Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016

Perennial Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016

Perennial Allergic Rhinitis - Pipeline by Merck & Co., Inc., H2 2016

Perennial Allergic Rhinitis - Pipeline by Pfizer Inc., H2 2016

Perennial Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2016

Perennial Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Perennial Allergic Rhinitis - Dormant Projects, H2 2016

Perennial Allergic Rhinitis - Discontinued Products, H2 2016 48List of Figures

Number of Products under Development for Perennial Allergic Rhinitis, H2 2016

Number of Products under Development for Perennial Allergic Rhinitis - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Faes Farma, S.A.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • MORE
According to our recently published report 'Perennial Allergic Rhinitis – Pipeline Review, H2 2016'; Perennial Allergic Rhinitis pipeline therapeutics constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says; Perennial Allergic Rhinitis Perennial allergic rhinitis is an allergy that occurs all year round and is caused by things such as house dust mites and pets. Symptoms include itching in the nose, roof of the mouth, throat, eyes, sneezing, stuffy nose (congestion), runny nose, tearing eyes and dark circles under the eyes. Treatment includes antihistamines, decongestants and corticosteroids.

The report 'Perennial Allergic Rhinitis – Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Perennial Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Perennial Allergic Rhinitis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III and Phase I stages are 2, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
Faes Farma, S.A.
Glenmark Pharmaceuticals Ltd.
Hisamitsu Pharmaceutical Co., Inc.
Merck & Co., Inc.
Pfizer Inc.
Shionogi & Co., Ltd.
VentiRx Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll